1-10 of 10
blast phase
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL– negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

Journal: Blood Advances
Blood Adv (2021) 5 (11): 2518.
https://doi.org/10.1182/bloodadvances.2021005068
Published: 2021
Journal Articles

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1 − MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Journal: Blood Advances
Blood Adv (2021) 5 (11): 2515.
https://doi.org/10.1182/bloodadvances.2021005066
Published: 2021
Journal Articles

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL –negative MPN in blast phase

Clinical Trials & Observations
Vikas Gupta, James A. Kennedy, Jose-Mario Capo-Chichi, Soyoung Kim, Zhen-Huan Hu, Edwin P. Alyea, Uday R. Popat, Ronald M. Sobecks, Bart L. Scott, Aaron T. Gerds, Rachel B. Salit, H. Joachim Deeg, Ryotara Nakamura, Wael Saber
Journal: Blood Advances
Blood Adv (2020) 4 (21): 5562–5573.
https://doi.org/10.1182/bloodadvances.2020002727
Published: 2020
Includes: Supplemental data
Journal Articles

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Clinical Trials & Observations
Shady Adnan Awad, Matti Kankainen, Teija Ojala, Perttu Koskenvesa, Samuli Eldfors, Bishwa Ghimire, Ashwini Kumar, Soili Kytölä, Mahmoud M. Kamel, Caroline A. Heckman, Kimmo Porkka, Satu Mustjoki
Journal: Blood Advances
Blood Adv (2020) 4 (3): 546–559.
https://doi.org/10.1182/bloodadvances.2019000943
Published: 2020
Includes: Supplemental data
Journal Articles

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Clinical Trials & Observations
Raajit K. Rampal, John O. Mascarenhas, Heidi E. Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark L. Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, Ronald Hoffman
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3572–3580.
https://doi.org/10.1182/bloodadvances.2018019661
Published: 2018
Includes: Supplemental data
Journal Articles

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, Sandeep Jain, Amer Assal, Jan Cerny, Edward A. Copelan, Andrew Daly, Zachariah DeFilipp, Shahinaz M. Gadalla, Robert Peter Gale, Siddhartha Ganguly, Betty K. Hamilton, Gerhard Carl Hildebrandt, Jack W. Hsu, Yoshihiro Inamoto, Abraham S. Kanate, H. Jean Khoury, Hillard M. Lazarus, Mark R. Litzow, Sunita Nathan, Richard F. Olsson, Attaphol Pawarode, Olle Ringden, Jacob M. Rowe, Ayman Saad, Bipin N. Savani, Harry C. Schouten, Sachiko Seo, Nirav N. Shah, Melhem Solh, Robert K. Stuart, Celalettin Ustun, Ann E. Woolfrey, Jean A. Yared, Edwin P. Alyea, Matt E. Kalaycio, Uday Popat, Ronald M. Sobecks, Wael Saber
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2922–2936.
https://doi.org/10.1182/bloodadvances.2018024844
Published: 2018
Includes: Supplemental data
Journal Articles

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

Clinical Trials & Observations
Caroline J. McNamara, Tony Panzarella, James A. Kennedy, Andrea Arruda, Jaime O. Claudio, Georgina Daher-Reyes, Jenny Ho, Nancy Siddiq, Rebecca Devlin, Hubert Tsui, Jie Su, Tracy Stockley, Mahadeo Sukhai, Nisha Kanwar, Steven Chan, Dawn Maze, Aaron Schimmer, Andre Schuh, Hassan Sibai, Auro Viswabandya, Karen Yee, Mark D. Minden, Suzanne Kamel-Reid, Vikas Gupta
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2658–2671.
https://doi.org/10.1182/bloodadvances.2018021469
Published: 2018
Includes: Supplemental data
Journal Articles

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Clinical Trials & Observations
Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi
Journal: Blood Advances
Blood Adv (2018) 2 (4): 370–380.
https://doi.org/10.1182/bloodadvances.2018015875
Published: 2018
Includes: Supplemental data
Journal Articles

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Clinical Trials & Observations
Jay Y. Spiegel, Caroline McNamara, James A. Kennedy, Tony Panzarella, Andrea Arruda, Tracy Stockley, Mahadeo Sukhai, Mariam Thomas, Justyna Bartoszko, Jenny Ho, Nancy Siddiq, Dawn Maze, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen Yee, Jamie Claudio, Rebecca Devlin, Mark D. Minden, Suzanne Kamel-Reid, Vikas Gupta
Journal: Blood Advances
Blood Adv (2017) 1 (20): 1729–1738.
https://doi.org/10.1182/bloodadvances.2017009530
Published: 2017
Includes: Supplemental data
Journal Articles

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia

Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, Mike Hamblin, Lisa Robinson, Richard E. Clark, Mhairi Copland, Paresh Vyas
Journal: Blood Advances
Blood Adv (2016) 1 (3): 160–169.
https://doi.org/10.1182/bloodadvances.2016000810
Published: 2016
Includes: Supplemental data